Literature DB >> 16731547

Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men.

M Cristina Meriggiola1, S Cerpolini, W J Bremner, M T Mbizvo, K M Vogelsong, G Martorana, G Pelusi.   

Abstract

BACKGROUND: We assessed attitudes towards and acceptability of male hormonal contraception among volunteers participating in a clinical trial of a prototype regimen, consisting of progestin and testosterone injections.
METHODS: After completing screening, eligible men were randomly assigned to the no-treatment group (n = 40) or to receive injections of norethisterone enanthate and testosterone undecanoate or placebo at different intervals (n = 50) according to a blocked randomization list. They underwent self-administered questionnaires.
RESULTS: The average age of the participants was approximately 28 years; most were involved in a stable relationship and had no children. Ninety-two percentage of the respondents thought that men and women should share responsibility for contraception and 75% said they would try a hormonal contraceptive if available. At the end of the treatment phase, 66% of the participants said that they would use such a method, and most rated its acceptability very highly; none reported it to be unacceptable. The injections themselves were indicated as the biggest disadvantage. No significant changes in sexual function or mood states were detected among the men who underwent hormone injections.
CONCLUSIONS: The contraceptive tested in this study was well accepted by the participants over the course of 1 year.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731547     DOI: 10.1093/humrep/del094

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  18 in total

1.  Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial.

Authors:  Mara Y Roth; Grace Shih; Niloufar Ilani; Christina Wang; Stephanie T Page; William J Bremner; Ronald S Swerdloff; Regine Sitruk-Ware; Diana L Blithe; John K Amory
Journal:  Contraception       Date:  2014-06-02       Impact factor: 3.375

2.  Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate.

Authors:  Gideon Sartorius; Carolyn Fennell; Sasa Spasevska; Leo Turner; Ann J Conway; David J Handelsman
Journal:  Asian J Androl       Date:  2010-02-01       Impact factor: 3.285

3.  Contraceptive sex acceptability: a commentary, synopsis and agenda for future research.

Authors:  Jenny A Higgins; Anne R Davis
Journal:  Contraception       Date:  2014-03-11       Impact factor: 3.375

Review 4.  Recent methodological advances in male hormonal contraception.

Authors:  Peter Y Liu; Ronald S Swerdloff; Christina Wang
Journal:  Contraception       Date:  2010-05-21       Impact factor: 3.375

5.  Vasectomy by epithelial curettage without suture or cautery: a pilot study in humans.

Authors:  John K Amory; John W Jessen; Charles Muller; Richard E Berger
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

Review 6.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 7.  Beyond the Condom: Frontiers in Male Contraception.

Authors:  Mara Y Roth; John K Amory
Journal:  Semin Reprod Med       Date:  2016-03-04       Impact factor: 1.303

8.  Modeling the impact of novel male contraceptive methods on reductions in unintended pregnancies in Nigeria, South Africa, and the United States.

Authors:  Emily Dorman; Brian Perry; Chelsea B Polis; Lisa Campo-Engelstein; Dominick Shattuck; Aaron Hamlin; Abigail Aiken; James Trussell; David Sokal
Journal:  Contraception       Date:  2017-09-05       Impact factor: 3.375

Review 9.  Male hormonal contraception: looking back and moving forward.

Authors:  M Y Roth; S T Page; W J Bremner
Journal:  Andrology       Date:  2015-10-09       Impact factor: 3.842

10.  Acceptability of oral dimethandrolone undecanoate in a 28-day placebo-controlled trial of a hormonal male contraceptive prototype.

Authors:  Brian T Nguyen; Maritza T Farrant; Bradley D Anawalt; Fiona Yuen; Arthi Thirumalai; John K Amory; Ronald S Swerdloff; William J Bremner; Peter Y Liu; Diana L Blithe; Stephanie T Page; Christina Wang
Journal:  Contraception       Date:  2020-04-13       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.